Live Oak Health Sciences holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Live Oak Health Sciences Fund LOGSX
- NAV / 1-Day Return 24.17 / −0.08 %
- Total Assets 50.9M
-
Adj. Expense Ratio
1.040%
- Expense Ratio 1.040%
- Distribution Fee Level Above Average
- Share Class Type Institutional
- Category Health
- Investment Style Mid Value
- Min. Initial Investment 2,000
- Status Open
- TTM Yield 0.10%
- Turnover 24%
USD | NAV as of Jun 13, 2026 | 1-Day Return as of Jun 13, 2026, 1:03 AM GMT+0
Morningstar’s Analysis LOGSX
Will LOGSX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the LOGSX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of LOGSX’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 51.1
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
United Therapeutics Corp | 6.54 | 3M | Healthcare |
Cardinal Health Inc | 6.01 | 3M | Healthcare |
McKesson Corp | 5.12 | 3M | Healthcare |
Novartis AG ADR | 5.10 | 3M | Healthcare |
Cencora Inc | 5.02 | 3M | Healthcare |
Regeneron Pharmaceuticals Inc | 5.01 | 3M | Healthcare |
Amgen Inc | 4.96 | 2M | Healthcare |
Jazz Pharmaceuticals PLC | 4.82 | 2M | Healthcare |
Exelixis Inc | 4.48 | 2M | Healthcare |
Johnson & Johnson | 4.02 | 2M | Healthcare |
United States